氯沙坦对原发性高血压患者左心室重塑的影响  

Effect of losartan on left ventricular remodeing in essential hypertensive

作　　者：汤宝鹏[1] 孙惠萍[1] 马依彤[1] 程祖亨[1] 杨毅宁[1] 张燕一[1] 

机构地区：[1]新疆医科大学第一附属医院心内科,新疆乌鲁木齐830054

出　　处：《新疆医科大学学报》2003年第5期416-418,共3页Journal of Xinjiang Medical University

摘　　要：目的 :探讨氯沙坦在治疗原发性高血压中对左心室重塑的预防和逆转的作用。 方法 :12 0例原发性高血压患者随机分为氯沙坦组和对照组 (波依定组 ) ,入院时行超声心动图测定室间隔厚度 (IVSd)、左心室后壁厚度(LVPW ) ,并计算左心室重量指数 (LVMI)。治疗 6个月后复查上述指标。 结果 :(1)对照组治疗后LVPW和IVSd有变薄的趋势 ,但差异无统计学意义 ,治疗 6个月后LVMI下降且具有统计学意义 (P <0 .0 5 ) ;(2 )氯沙坦组治疗 6个月后LVPW、IVSd、LVMI均有改善 ,且具有统计学意义 (P <0 .0 5 ) ;(3)两组间降压幅度差异无统计学意义。 结论 :降低血压可抑制和逆转左心室重塑 ,但血管紧张素Ⅱ受体拮抗剂还具有降压外的消退和预防左心室肥厚及改善左心室舒张功能的作用 ,其抑制和逆转左心室重塑 ,保护心脏功能作用优于钙离子拮抗剂。Objective: This study was to investigate the effect of losartan on left ventricular remodeling in essential hypertensive. Methods: One handred and twenty patients with essential hypertensive (heart funtion typeⅠ Ⅱ, hypertensive type 2 3) were randomly divided into 2 groups: losartan group, poyidin group. The parameters of LVMI, IVSd, LVPW were examined by echocardiography, and LVMI was measured before, and after therapy. Results: (1) In poyidin group, left ventricular septum thickness and posterior wall thickness showed the trend of decreasing, but have no statistically significant (P>0.05), leftventricular mass index reduced significantly (P<0.05) before and after therapy. (2) In losartan group, leftventricular septum thickness? posterior wall thickness and left ventricular mass index decreased significantly comparing with those before treatment and the controls (P<0.05). (3) There was no significant difference on range of decompression between two groups. Conclusion: Treatment of hypertension can depress and reverse left ventricular remodeling in patients with essential hypertension. But angiotensin Ⅱ antagonist has more effective to delay and depress the development left ventricular remodeling besides treatment of hypertension. Its effects on depreing and reversing left ventricular remodeling are better than that in poyidin group.

关 键 词：氯沙坦 原发性高血压 左心室重塑 

分 类 号：R972[医药卫生—药品] R541.3[医药卫生—药学]